OSAKA -- Ono Pharmaceutical will develop a diagnostic test to identify patients who would benefit from its Opdivo cancer drug, allowing for more efficient treatment and lower medical costs.
The Japanese drugmaker assembled a team of six companion-diagnostics researchers to identify relevant cancer biomarkers. They already have found one marker that determines how well a patient could respond to the drug.
